Sign In
Buy ARVN
$8.03
-0.270 (-3.25%)
At Close: Jul 31, 2026
Arvinas, Inc. (NASDAQ:ARVN) Sees Large Drop in Short Interest
02:15am, Monday, 16'th Feb 2026
Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 4,262,275 shares, a dr
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
07:00am, Thursday, 12'th Feb 2026
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb.
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Hold” from Brokerages
03:12am, Saturday, 31'st Jan 2026
Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) has been assigned an average rating of "Hold" from the twenty-two brokerages that are presently covering the company, MarketBeat reports. Two research an
Arvinas (NASDAQ:ARVN) Shares Down 2.6% – Should You Sell?
02:22am, Tuesday, 06'th Jan 2026
Shares of Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) traded down 2.6% during mid-day trading on Monday. The company traded as low as $11.01 and last traded at $11.17. 684,941 shares traded hands d
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN
04:10am, Monday, 15'th Dec 2025
Caxton Associates LLP bought a new stake in Arvinas, Inc. (NASDAQ: ARVN) in the undefined quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the company's
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of “Hold” from Analysts
02:11am, Friday, 12'th Dec 2025
Shares of Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) have been assigned an average rating of "Hold" from the twenty-three research firms that are currently covering the stock, Marketbeat reports.
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lympho
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
07:00am, Wednesday, 26'th Nov 2025
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
54,832 Shares in Arvinas, Inc. $ARVN Purchased by Campbell & CO Investment Adviser LLC
05:12am, Monday, 17'th Nov 2025
Campbell and CO Investment Adviser LLC acquired a new stake in Arvinas, Inc. (NASDAQ: ARVN) during the second quarter, according to the company in its most recent disclosure with the Securities and Ex
Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript
03:01pm, Wednesday, 05'th Nov 2025
Arvinas, Inc. ( ARVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - Chairperson, CEO & President Noah Berkow
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
09:21am, Wednesday, 05'th Nov 2025
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $0.68 per share a year ago.
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 05'th Nov 2025
– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust a
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
04:00pm, Monday, 03'rd Nov 2025
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Monday, 03'rd Nov 2025
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
